14 Parathyroid

Vitamin D

_arrow-up-right..

_arrow-up-right

Endogenous vitamin D is produced by photoconversion of 7-dehydrocholesterol to vitamin D3 in sun-exposed skin in the stratum basale (most important source)..

_arrow-up-right..

  • 25-OH storage form

_arrow-up-right..

  • constant production

  • long half life

_arrow-up-right..

_arrow-up-right..

  • Mostly increase Ca and bone mineralization (add Ca to bone). At very high levels can cause bone resorption.

_arrow-up-rightThe effects of vitamin D in the intestines include increasing the absorption of Ca 2+ via induction of vitamin-D dependent Ca2+-binding protein (calbindin-D-28K), and increasing the absorption of phosphate by upregulating Na-Pi symporter..

Deficiency

_arrow-up-right..

Osteomalacia

_arrow-up-right..

Rickets

_arrow-up-right

.,

_arrow-up-right..

Excess

_arrow-up-right..

  • loss of appetite and stupor (unconsciousness)

Osteoporosis drugs

Bisphosphonates

_arrow-up-rightThe first-line treatment for osteoporosis. They induce apoptosis and inhibit differentiation and activity in osteoclasts (block osteoclast binding and the formation of the osteoclastic ruffled border). Bisphosphonates also appear to bind to the hydroxyapatite of the bone, stabilizing it against recognition by the osteoclasts.,

_arrow-up-rightExamples include the “-dronate” drugs:

  • Medronate

  • Clodronate

  • Alendronate.,

_arrow-up-rightUses:

  • Osteoporosis

  • Hypercalcemia

  • Bone malignancy

  • Paget disease of the bone.,

_arrow-up-rightSE include:

  • Esophagitis (patients are advised to take with water and remain upright for 30 minutes)

  • Dysphagia

  • Gastric ulcers

  • Osteonecrosis of the jaw.,

SERMS

_arrow-up-rightselective estrogen receptor modulators.,

_arrow-up-rightHave tissue specific effects. In some tissues they behave as estrogen agonists whereas in other tissues they behave as estrogen antagonists.,

_arrow-up-rightInclude tamoxifen and raloxifene.,

Raloxifene

_arrow-up-rightInhibits bone resorption by acting as an estrogen agonist in the bone. It can be successfully combined with bisphosphonates to prevent osteoporosis in postmenopausal women.,

_arrow-up-rightIinhibits bone resorption in postmenopausal women by inhibiting osteoclasts. However because of the increased risk of endometrial hyperplasia and cancer, is NOT considered a first-line SERM for the treatment of osteoporosis.,

_arrow-up-rightSome common side effects include:

  • Edema

  • Hot flashes

  • Arthralgias

Note that both cause decreased bone density in premenopausal women, so they should NOT be used to treat or prevent osteoporosis in this population.

Serious adverse effects include:

  • Venous thromboembolism

  • Fatal stroke in patients with cardiovascular disease

  • Endometrial cancer.,

Teriparatide

_arrow-up-rightHas been shown to increase bone density and bone mass.

In postmenopausal women, decreases osteoporosis-related fractures.

Should not be used in patients with previous bone radiation or other predispositions to osteosarcoma.,

Denosumab

_arrow-up-rightA human monoclonal anti-RANKL antibody used for the treatment of:

  • Osteoporosis

  • Treatment-induced bone loss

  • Bone metastases

  • Multiple myeloma

  • Giant cell tumor of bone.,

_arrow-up-right Adverse effects include:

  • Joint and muscle pain in the arms or legs

  • Increased risk of infection

  • Hypocalcemia

  • Osteonecrosis of the jaw

  • Atypical hip fractures (from too little bone turn over).,

Calcium

_arrow-up-rightPlasma Ca2+ exists in three forms:

  • Free ionized (45%)

  • Bound to albumin (40%)

  • Bound to anions (15%)..

Free, ionized Ca2+ is biologically active.

_arrow-up-right

Ionized calcium binds to negatively charged sites on protein molecules, competing with hydrogen ions for the same binding sites on albumin and other calcium-binding proteins.

This binding is pH dependent and alters the level of ionized calcium in the blood. An increase in pH, alkalosis, promotes increased protein binding (less H+ competing), which decreases free calcium levels. Acidosis, on the other hand, decreases protein binding, resulting in increased free calcium levels..

_arrow-up-rightDiuretics can alter calcium levels. Loop diuretics decrease calcium reabsorption in the thick ascending limb of the nephron, while thiazides increase its reabsorption in the distal convoluted tubule. To remember this difference, use the mnemonic "The loop loses calcium"..

_arrow-up-rightActive reabsorption by the Na+/K+/2Cl- cotransporter leads to a backleak of K+. The positive lumen potential created by this backleak will induce paracellular reabsorption of Mg2+ and Ca2+. Blocking the Na+/K+/2Cl- cotransporter with a loop diuretic will decrease calcium reabsorption into the blood..

_arrow-up-rightThiazide diuretics block the apical Na+/Cl- symporter, and as a result intracellular sodium is reduced. This ramps up the activity of the basolateral Ca2+/Na+ exchanger (to increase Na+ pumped into the tubular cell), which will increase calcium reabsorption into the blood..

Cinacalcet

_arrow-up-rightIncreases the sensitivity of the Ca2+-sensing receptor (CaSR) in the parathyroid gland to circulating Ca2+. This decreases the secretion of parathyroid hormone.,

_arrow-up-rightIs indicated in the treatment of:

  • Hypercalcemia due to primary hyperparathyroidism (e.g. parathyroid carcinoma)

  • Secondary hyperparathyroidism in chronic kidney disease patients

.,Cinacalcet may cause hypocalcemia.

PTH

_arrow-up-right

  • Soluble in water.,

Effects

_arrow-up-right..

_arrow-up-right..

_arrow-up-right..

  • 1, 25 OH2 Vit D is active form

  • Overall effect: decreased phosphate in serum

_arrow-up-right..

  • Decreased phosphate in serum

  • Increased phosphate secretion

_arrow-up-right..

_arrow-up-right..

_arrow-up-rightParathyroid analog used to treat osteoporosis.,

_arrow-up-right..

_arrow-up-right..

  • OPG is secreted by osteoblast. It's a soluble RANk that inactivates RANK-L

_arrow-up-right..

  • pregnancy: increased estrogen and bone density

  • stress: increased glucocorticoids and decreased bone density

_arrow-up-right..

_arrow-up-right..

  • Low Mg leads to increased GI/renal absorption

_arrow-up-right..

PTHrp

_arrow-up-right.,

Hyperparathyroidism

_arrow-up-right.,

Primary Hyperparathyroidism

_arrow-up-rightCause:

.,

_arrow-up-right

  • Increased cAMP

  • Increased Alk Phos: alkaline environment needed to lay down Ca in bone. Increased osteoblast > increased laying down bone and produce alk phos (sign of osteoblast activity)

.,

_arrow-up-rightSymptoms:

  • malignancy: symptoms happens earlier

  • metastatic calcification of renal tubules

  • classic: pancreatitis

  • nephrocalcinosis:

.,

Osteitis Fibrosa Cystica

_arrow-up-right

.,

  • Cystica means bone change

_arrow-up-right

  • Periosteum: membrane surrounding the bone

.,

_arrow-up-rightHistology shows fibrosis and bone spicules

.,

Primary hyperparathyroidism treatment

_arrow-up-right

  • post-op: takes time for remaining glands to start working.,

Secondary

_arrow-up-right

  • bone pain from PTH

  • high alk phos

.,

Tertiary

_arrow-up-right

.,

  • parathyroid independent of Ca

_arrow-up-right..

  • Can't excrete phosphate > more binding with Ca

  • Can't activate Vit D > Less Ca reabsorption

Familial hypocalciuria hypercalcemia

_arrow-up-right

.,

Hypoparathyroidism

_arrow-up-right

.,

_arrow-up-right

.,

_arrow-up-right

  • Autoimmune

  • Congenital: DiGeorge

  • Radiation

.,

  • post-op: days/weeks later

APS-1

_arrow-up-right

.,

Digeorge

_arrow-up-right..

  • thymic aplasia

_arrow-up-right

.,

Pseudohypoparathyroidism

_arrow-up-right

  • Gs receptors

.,

  • Named pseudo because has signs and symptoms of hypoparathyroidism but not because of low hypoparathyroidism.

Albright's Hereditary Osteodystrophy, AHO

[_](Albright's Hereditary Osteodystrophy, AHO, inheritance, labs, symptoms)

.,

  • Increased PTH, decreased Ca: Ca lost somewhere

_arrow-up-right..

Ddx

  • Hypercalcemia

  • Hyperparathyroidism workup:

Last updated